人福醫藥(600079.SH):注射用磷丙泊酚二鈉獲得藥品註冊證書
格隆匯5月25日丨人福醫藥(600079.SH)公佈,公司控股子公司宜昌人福藥業有限責任公司(“宜昌人福”,公司持有其80%的股權)近日收到國家藥品監督管理局核准簽發的注射用磷丙泊酚二鈉的《藥品註冊證書》。
注射用磷丙泊酚二鈉是一種新型短效靜脈全身麻醉藥,在體內被代謝成活性物質丙泊酚後產生麻醉作用。丙泊酚是目前臨牀廣泛使用的一種靜脈全身麻醉藥,根據米內網數據顯示,2020年注射用丙泊酚在我國城市、縣級及鄉鎮三大終端公立醫院的銷售額約為人民幣34億元。注射用磷丙泊酚二鈉不需要丙泊酚製劑的脂肪乳載體,臨牀應用中可減輕靜脈注射疼痛,同時避免脂肪乳載體可能導致的脂代謝紊亂。本次獲批的適應症為靜脈用全身麻醉劑,用於成人全身麻醉的誘導。宜昌人福於2018年10月向國家藥品監督管理局提交注射用磷丙泊酚二鈉上市申請,截至目前該項目累計投入約為人民幣7000萬元。
本次注射用磷丙泊酚二鈉獲批後,宜昌人福將根據市場需求情況,着手安排生產上市。該產品充實了公司產品線,其上市銷售將對公司帶來積極影響。該產品未來的具體銷售情況可能受到行業政策、市場環境等因素影響,具有不確定性,敬請廣大投資者謹慎決策,注意防範投資風險。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.